Etelcalcetide

Generic Name
Etelcalcetide
Brand Names
Parsabiv
Drug Type
Small Molecule
Chemical Formula
C38H73N21O10S2
CAS Number
1262780-97-1
Unique Ingredient Identifier
60ME133FJB
Background

Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.

Indication

Etelcalcetide is a calcium-sensing receptor agonist indicated for:

Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

Associated Conditions
Secondary Hyperparathyroidism (SHPT)
Associated Therapies
-
amgen.com
·

AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

Amgen reports Q3 2024 financial results: total revenues up 23% to $8.5 billion, GAAP EPS increased 62% to $5.22, non-GAAP EPS up 13% to $5.58, driven by strong product sales and pipeline investments.
© Copyright 2024. All Rights Reserved by MedPath